chadds ford, pa endo
Post on 30-Dec-2015
17 Views
Preview:
DESCRIPTION
TRANSCRIPT
Combined PPC/Endo Pipeline/Stage of Development
Compound Indication Discovery PC Phase 1 Phase II Phase III
Frova menstrual migraine
Rapinyl breakthrough cancer pain
Ketoprofen Patchacute pain (soft tissue inj)
LidoPAIN BP acute lower back pain
Lidoderm other indications; not PHN
EN3285 oral mucositis
CHRONOGESIC Chronic mod-severe pain
Sufentanil Patch Chronic mod-severe pain
NGF/p75-trkA
ASIC 1
ASIC 3
Confidential1
Chadds Ford, PA www.endo.com
Transaction Rationale– Endo seeks & PPC can provide: Additional validated pain products for a primarily late stage pipeline. Secondary indications may be of interest to Endo, as they are looking to expand into related markets.
PPC seeks & Endo can provide: US presence and access to US stock exchange, Phase II & III products, experience developing topical analgesic treatment, strong financial position.
Company Description - Endo Pharmaceuticals Holdings Inc was established in 1920 as a specialty pharmaceutical company focused on developing branded and generic treatments for pain. Flagship products include the Lidoderm patch and Percocet. In July 2004, Endo obtained exclusive rights to market Vernalis‘ [menstrually associated] migraine therapy, frovatriptan. They currently hold the rights to commercialize EpiCept’s LidoPAIN BP for acute low back pain, and have 8 products in clinical development. Endo’s 2006 sales were $909.7M USD. The company currently has approximately 1000 employees.
Therapeutic Areas
• Pain- Chronic
•Pain- Acute
• Pain- Neuropathic
•Neurology, Oncology
5 June 2007
Management
Peter A. Lankau CEO, President
Dr. David A.H. Lee CSO, VP, R&DCaroline B. Manogue Chief Legal Officer, SecretaryCharles A. Rowland, Jr. CFO, Treasurer
Board of Directors
Carol A. Ammon Chairman of the Board
John J. Delucca
Michel de Rosen
George F. Horner III
Michael Hyatt
Roger H. Kimmel
Peter A. Lankau
Dr. Clive A. Meanwell
Financial Snapshot ($USD million, except for Share Prices, or unless otherwise stated)
Symbol ENDP Shares O/S 133.60 Revenues (ttm) ###### Top Institutional Holders
Share Price $35.03 Mkt. Cap. 4.68 B Income (ttm) $174.45 Capital Research & Mgmt Co. 9.19%
52-Week High $35.3 Cash $730.9 Price/Sales 4.84 Barclays Global Investors UK Ltd 6.13%
Low $26.68 Tech. Value $4.0 Quarterly Burn $0.68 Royce & Associates, Inc. 5.88%
top related